Share on LinkedInShare on LinkedIn

ARTICLE · 04 MARCH 2024

EU Report: Antitrust Enforcement For Broader Pharmaceutical Access – Strengthening Compliance Amid Robust Measures

CBC Law
CBC Law
Contributor
CBC Law

CBC Law

CBC Law is an independent, full-service law firm serving local and international clients. With...

View firm profile
Explore more from CBC Law

Explore the EU antitrust impact on pharmaceuticals (2018-2022). The recent report underscores the pivotal role of antitrust measures—promoting fair medicine prices...

European UnionAntitrust/Competition Law

Explore the EU antitrust impact on pharmaceuticals (2018-2022). The recent report underscores the pivotal role of antitrust measures—promoting fair medicine prices, addressing anticompetitive practices, and shaping the future of pharmaceutical enforcement in Europe. In times of robust enforcement in both the EU and Türkiye, strategic compliance becomes imperative, providing pharmaceutical companies with a competitive edge.

What is the Purpose and Scope of the Report?

The European Commission released a report on January 26, 2024, assessing the enforcement of EU antitrust and merger regulations in the pharmaceutical industry from 2018 to 2022. In collaboration with the national competition authorities ("NCAs") of the 27 EU Member States through the European Competition Network ("ECN")1, the study focused on medications and certain medical items.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from